Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 5Genitourinary 4Gastrointestinal 4Thoracic 3Sarcoma 3Lymphoid 3Gynecologic 3Plasma cell 2Other hematologic neoplasm 2NET 2Endocrine 2Head & Neck 1Breast 1

Conditions

Ovarian Neoplasms 805Uterine Cervical Neoplasms 412Fallopian Tube Neoplasms 289Endometrial Neoplasms 287Carcinoma, Ovarian Epithelial 252Neoplasms 95Recurrence 83Breast Neoplasms 83Peritoneal Neoplasms 66Uterine Neoplasms 55Colorectal Neoplasms 55Uterine Cervical Dysplasia 50Sarcoma 49Vulvar Neoplasms 47Carcinoma, Non-Small-Cell Lung 45Neoplasm Metastasis 44Stomach Neoplasms 42Pancreatic Neoplasms 36Melanoma 34Testicular Neoplasms 32Lung Neoplasms 32Prostatic Neoplasms 29Vaginal Neoplasms 28Papillomavirus Infections 25Carcinoma 25Head and Neck Neoplasms 23Esophageal Neoplasms 23Carcinoma, Renal Cell 23Small Cell Lung Carcinoma 22Urinary Bladder Neoplasms 21

Interventions

tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × Gynecologic × Clear all
NCT03804866 2019-01-15

NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

AGC Biologics S.p.A.

Phase 2 Completed
14 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT01358071 2018-09-27

NGR018

AGC Biologics S.p.A.

Phase 2 Completed
119 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Disease Progression

NCT00517621 2011-02-25

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

ARCAGY/ GINECO GROUP

Phase 2 Completed
100 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡